基因多态性对他克莫司血药浓度影响的研究进展  

Research progress on the influence of gene-polymorphisim on blood drug level of tacrolimu

作　　者：李敏 李峰[1] 高鑫[1] 

机构地区：[1]解放军88医院肾内科,山东泰安271000 [2]泰山医学院

出　　处：《实用医药杂志》2017年第2期162-164,共3页Practical Journal of Medicine & Pharmacy

摘　　要：药物的临床疗效与血药浓度相关密切,他克莫司(FK506)的药动学个体之间差异大、其有效剂量与中毒剂量之间的安全范围窄、不良反应大且较易受其他联合用药的影响,因此,需要监测FK506的血药浓度以实现个体化用药,以确保用药的安全性和有效性。研究表明,代谢酶的遗传多态性是导致个体和个体代谢能力差异的原因之一,其对药物治疗及不良反应有重要的影响。Clinical efficacy and blood drugs level are closely related each other,tacrolimu＇s （FK506） pharmacokinetic states has significant individual difference,its safe range of the effective dose and the toxic dose was narrow,and the adverse reactions was large,which also easily affected by other drugs in combination of medication. Therefore,it is necessary to monitor the blood drug level of FK506,so as to realize individual drug use,thus ensure the safety and effectiveness of the drug. The research results show that the genetic polymorphisms of metabolic enzymes is one of the reasons that lead to the differences between individuals and individual＇s metabolic ability ,and it has an important influence on medication and adverse reactions.

关 键 词：他克莫司 CYP3 A4基因 CYP3 A5基因 ABCB1基因 

分 类 号：R969.3[医药卫生—药理学]